Eric Kort1,2,3, Stefan Jovinge4,5,6. 1. DeVos Cardiovascular Research Program, Van Andel Institute/Spectrum Health, Grand Rapids, MI, USA. 2. Dept of Pediatrics & Human Development, Michigan State University, Grand Rapids, MI, USA. 3. Helen DeVos Children's Hospital, Grand Rapids, MI, USA. 4. DeVos Cardiovascular Research Program, Van Andel Institute/Spectrum Health, Grand Rapids, MI, USA. Stefan.jovinge@vai.org. 5. Frederik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI, USA. Stefan.jovinge@vai.org. 6. Cardiovascular Institute, Stanford University, Palo Alto, CA, USA. Stefan.jovinge@vai.org.
Abstract
PURPOSE OF REVIEW: Drug development has evolved over the years from being one-at-a-time to be massive screens in an industrial manner. Bringing a new therapeutic agent from concept to bedside can take a decade and cost billions of dollars-with most concepts failing along the way. Of the few compounds that make it to clinical testing, less than one out of eight make it to approval. This traditional drug development pipeline is challenging for prevalent diseases and makes the development of new therapeutics for rare diseases financially intractable. RECENT FINDINGS: Repurposing of drugs is an alternative to identify new applications for the thousands of compounds that have already been approved for clinical use. There is now a range of strategies for such efforts that leverage clinical data, pharmacologic data, and/or genomic or transcriptomic data. These strategies, together with examples, are detailed in this review. Drug repurposing bypasses the pre-clinical work and thereby opens up the opportunity to provide targeted treatment at a fraction of the cost that is accompanied with the development from ideation to full approval. Such an approach makes drug discovery for any disease process more efficient but holds particular promise for rare diseases for which there is little to no other viable drug development channel.
PURPOSE OF REVIEW: Drug development has evolved over the years from being one-at-a-time to be massive screens in an industrial manner. Bringing a new therapeutic agent from concept to bedside can take a decade and cost billions of dollars-with most concepts failing along the way. Of the few compounds that make it to clinical testing, less than one out of eight make it to approval. This traditional drug development pipeline is challenging for prevalent diseases and makes the development of new therapeutics for rare diseases financially intractable. RECENT FINDINGS: Repurposing of drugs is an alternative to identify new applications for the thousands of compounds that have already been approved for clinical use. There is now a range of strategies for such efforts that leverage clinical data, pharmacologic data, and/or genomic or transcriptomic data. These strategies, together with examples, are detailed in this review. Drug repurposing bypasses the pre-clinical work and thereby opens up the opportunity to provide targeted treatment at a fraction of the cost that is accompanied with the development from ideation to full approval. Such an approach makes drug discovery for any disease process more efficient but holds particular promise for rare diseases for which there is little to no other viable drug development channel.
Authors: Philippe Sanseau; Pankaj Agarwal; Michael R Barnes; Tomi Pastinen; J Brent Richards; Lon R Cardon; Vincent Mooser Journal: Nat Biotechnol Date: 2012-04-10 Impact factor: 54.908
Authors: Wendy W Chapman; Prakash M Nadkarni; Lynette Hirschman; Leonard W D'Avolio; Guergana K Savova; Ozlem Uzuner Journal: J Am Med Inform Assoc Date: 2011 Sep-Oct Impact factor: 4.497
Authors: Andre Franke; Dermot P B McGovern; Jeffrey C Barrett; Kai Wang; Graham L Radford-Smith; Tariq Ahmad; Charlie W Lees; Tobias Balschun; James Lee; Rebecca Roberts; Carl A Anderson; Joshua C Bis; Suzanne Bumpstead; David Ellinghaus; Eleonora M Festen; Michel Georges; Todd Green; Talin Haritunians; Luke Jostins; Anna Latiano; Christopher G Mathew; Grant W Montgomery; Natalie J Prescott; Soumya Raychaudhuri; Jerome I Rotter; Philip Schumm; Yashoda Sharma; Lisa A Simms; Kent D Taylor; David Whiteman; Cisca Wijmenga; Robert N Baldassano; Murray Barclay; Theodore M Bayless; Stephan Brand; Carsten Büning; Albert Cohen; Jean-Frederick Colombel; Mario Cottone; Laura Stronati; Ted Denson; Martine De Vos; Renata D'Inca; Marla Dubinsky; Cathryn Edwards; Tim Florin; Denis Franchimont; Richard Gearry; Jürgen Glas; Andre Van Gossum; Stephen L Guthery; Jonas Halfvarson; Hein W Verspaget; Jean-Pierre Hugot; Amir Karban; Debby Laukens; Ian Lawrance; Marc Lemann; Arie Levine; Cecile Libioulle; Edouard Louis; Craig Mowat; William Newman; Julián Panés; Anne Phillips; Deborah D Proctor; Miguel Regueiro; Richard Russell; Paul Rutgeerts; Jeremy Sanderson; Miquel Sans; Frank Seibold; A Hillary Steinhart; Pieter C F Stokkers; Leif Torkvist; Gerd Kullak-Ublick; David Wilson; Thomas Walters; Stephan R Targan; Steven R Brant; John D Rioux; Mauro D'Amato; Rinse K Weersma; Subra Kugathasan; Anne M Griffiths; John C Mansfield; Severine Vermeire; Richard H Duerr; Mark S Silverberg; Jack Satsangi; Stefan Schreiber; Judy H Cho; Vito Annese; Hakon Hakonarson; Mark J Daly; Miles Parkes Journal: Nat Genet Date: 2010-12 Impact factor: 38.330
Authors: Hua Xu; Melinda C Aldrich; Qingxia Chen; Hongfang Liu; Neeraja B Peterson; Qi Dai; Mia Levy; Anushi Shah; Xue Han; Xiaoyang Ruan; Min Jiang; Ying Li; Jamii St Julien; Jeremy Warner; Carol Friedman; Dan M Roden; Joshua C Denny Journal: J Am Med Inform Assoc Date: 2014-07-22 Impact factor: 4.497